PFE Add to watchlist $27.19 +0.08 (+0.30%) Last updated: Apr 16, 2026 00:32
52-Week Range
$27.19
$21.87 $27.19 $28.75

Fundamentals Overview

Pfizer Inc. is near the high of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/E 19.9 P/B 1.79 P/S 2.47

Intrinsic value (DCF)

+45.5% upside vs price

Profitability

Net margin 12.4%

Risk (Beta)

0.39 — lower vol

Earnings & growth

EPS $1.37 Rev +5.4% Profit -146.5% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 76% confidence Risk: Lower Volatility — Beta 0.39. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +45.5% upside vs price · Analyst grade: A- · 3M vs S&P 500: +6.9% · 3M vs Healthcare sector: +13.7%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$154.67B
P/E (TTM)
19.9
EPS (TTM)
$1.37
Dividend Yield
3.16%
52-Week Range
$21.87 - $28.75
Volume vs Avg
N/A
Beta
0.39

About

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 trea...
Sector: Healthcare
Headquarters: US
Employees: 81,000
IPO Date: Jun 1972
Beta: 0.39 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: A-. Recent institutional grades: mixed. Current institutional positions: Buy: 10, Equal Weight: 6, Neutral: 14.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $39.57; current price is $27.19. That’s a +45.5% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 19.9
DCF value (model) $39.57 (45.5% upside)
PEG (TTM) N/A
P/B (TTM) 1.79
P/S (TTM) 2.47
P/FCF (TTM) 17.04
Liquidity & enterprise
Current Ratio (TTM) 1.16
Quick Ratio (TTM) 0.87
Cash Ratio (TTM) 0.03
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 12.42%
Gross margin (TTM) 70.33%
Operating margin (TTM) 24.67%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for PFE.

Analyst Sentiment at a Glance

A- Sentiment Mixed
Buy 10Equal Weight 6Neutral 14
1 upgrade, 1 downgrade
Price Target Consensus
Current $27.19
Median $27.00
Consensus $27.50
Low consensus $24.00
High consensus $35.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
UBS maintain Neutral Neutral 2026-04-13
Morgan Stanley maintain Equal Weight Equal Weight 2026-04-10
B of A Securities maintain Neutral Neutral 2026-04-09
Guggenheim maintain Buy Buy 2026-03-24
HSBC maintain Buy Buy 2026-03-17
Argus Research upgrade Hold Buy 2026-03-02
Freedom Broker maintain Buy Buy 2026-02-09
Cantor Fitzgerald maintain Neutral Neutral 2026-02-04
Cantor Fitzgerald maintain Neutral Neutral 2026-01-27
Morgan Stanley maintain Equal Weight Equal Weight 2025-12-17
B of A Securities maintain Neutral Neutral 2025-12-15
Morgan Stanley maintain Equal Weight Equal Weight 2025-12-12
Guggenheim maintain Buy Buy 2025-11-24
Morgan Stanley maintain Equal Weight Equal Weight 2025-10-10
B of A Securities maintain Neutral Neutral 2025-10-03
Morgan Stanley maintain Equal Weight Equal Weight 2025-08-06
B of A Securities maintain Neutral Neutral 2025-08-06
Citigroup maintain Neutral Neutral 2025-08-06
UBS maintain Neutral Neutral 2025-04-30
UBS maintain Neutral Neutral 2025-04-08
Goldman Sachs downgrade Buy Neutral 2025-04-08
Guggenheim maintain Buy Buy 2025-03-18
Guggenheim maintain Buy Buy 2025-03-12
Guggenheim maintain Buy Buy 2025-02-10
UBS maintain Neutral Neutral 2025-02-05
Citigroup maintain Neutral Neutral 2025-01-28
UBS maintain Neutral Neutral 2025-01-08
Truist Securities maintain Buy Buy 2024-12-18
Guggenheim maintain Buy Buy 2024-12-11
Morgan Stanley maintain Equal Weight Equal Weight 2024-10-30